Hit or miss - Avis employé Senior Medical Director MSD

Life at Merck depends all on line manager and group. Overall, it has dramatically declined within a short time. Pembrolizumab is approaching the end of its life cycle and no real successor molecule is in sight, so the pressure is increasing. Merck has also become excessively woke, with promotions being largely driven by DEI and qualification no longer seems to matter.